Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of prostate cancer called adenocarcinoma, confirmed by a biopsy.
- People whose testosterone levels are very low (in the "castration" range, below 50 ng/ml or 1.7 nmol/L), meaning hormone therapy is keeping testosterone suppressed.
- People whose cancer has continued to grow or spread despite that hormone therapy, shown either through rising PSA levels (measured using a standard scale called the Phoenix criteria) or through imaging scans.
- People whose imaging scans (using a special type of scan called PSMA PET/CT or Choline PET/CT) show 5 or fewer areas where cancer has spread, limited to lymph nodes or bones only — not internal organs — and where those areas are small enough to be treated with a precise type of radiation called SBRT (confirm with trial site for exact size limits).
- People whose treating doctor has already decided, as part of routine care, that treatment with abiraterone or enzalutamide is appropriate, and where that treatment has either not yet started or started no more than 14 days before signing the consent form.
- People who are able to provide written consent to participate.
- People with a life expectancy of more than 3 months.
Who may not be able to join:
- People whose prostate cancer is a type other than adenocarcinoma.
- People who have not had a biopsy to confirm their diagnosis.
- People who have more than 5 areas where cancer has spread, or whose affected areas cannot be covered within 5 radiation treatment fields.
- People who have cancer that has spread to internal organs (such as the liver or lungs), or whose affected areas are not suitable for SBRT radiation treatment.
- People whose testosterone levels are above the castration range, meaning hormone therapy is not keeping testosterone sufficiently suppressed.
- People who have previously been treated with a chemotherapy drug called docetaxel specifically as a first treatment for castration-resistant prostate cancer. (Note: prior docetaxel treatment is allowed if it was given at an earlier stage, when the cancer was still responding to hormone therapy.)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marta Barrado Los Arcos, MD, Hospital of Navarra
Phone: +34 696633409
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the PRFS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.